A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations.

ESMO Open · 2024 · PMC11047177 · PMID 38640748

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

The association of splicing factor mutations (high-impact mutation) with CB showed a nonsignificant trend in patients with NSCLC but not in patients with HNSCC ( Supplementary Table S4 , available at https://doi.org/10.1016/j.esmoop.2024.102961 ).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.